http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-454004-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61c0b38c0948cdbce0b193c5279ab4a9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D521-00 |
| filingDate | 1997-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5716ba1c91f496a57ffd11d864e0ffb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77284231353f8f86d3b325604c3db15d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51dcb4bf9b7fce1cb999d60751721972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27e9cdfec7f2260790a00b0799413afa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7b21e02c7326eecd4a4946ab168a4e4 |
| publicationDate | 2001-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-454004-B |
| titleOfInvention | Quinoxalinediones |
| abstract | The invention provides compounds of the formula, and the pharmaceutically acceptable salts thereof, wherein R is a 5-membered ring heteroaryl group containing 3 or 4 nitrogen heteroatoms which is linked to the quinoxalinedione ring by a ring carbon or nitrogen atom, or is a 6-membered ring heteroaryl group containing from 1 to 3 nitrogen heteroatoms which is linked to the quinoxalinedione ring by a ring carbon atom, either or said groups being optionally benzo-fused and optionally substituted, including in the benzo-fused portion, by 1 or 2 substituents each independently selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C7 cycloalkyl, halo, hydroxy, C1-C4 alkoxy, C3-C7 cycloalkyloxy, -COOH, C1-C4 alkoxycarbonyl, -CONR3R4, -NR3R4, -S(O)p(C1-C4 alkyl), -SO2NR3R4, aryl, aryloxy, aryl(C1-C4)alkoxy, -COOH, C1-C4 alkoxycarbonyl, -CONR3R4, -NR3R4, -S(O)p(C1-C4 alkyl), -SO2(aryl), -SO2NR3R4, morpholino, aryl, aryloxy, aryl(C1-C4alkoxy or het, and said C2-C4 alkenyl being optionally substituted by aryl; R1 and R2 are each independently selected from H, fluoro, chloro, bromo, C1-C4 alkyl and halo(C1-C4)alkyl; R3 and R4 are either each independently selected from H and C1-C4 alkyl or, when taken together, are C5-C7 alkylene; p is 0, 1 or 2; ""aryl"", used in the definition of R and ""het"", means phenyl or naphthyl, each optionally substituted by 1 or 2 substituents each independently selected from C1-C4 alkyl, C1-C4 alkoxy, hydroxy, halo, halo(C1-C4)alkyl and -NR3R4; ""het"", used in the definition of R, means furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each being optionally benzo-fused and optionally substituted, including in the benzo-fused portion, by 1 or 2 substituents each independently selected from C1-C4 alkyl, C3-C7 cycloalkyl, C1-C4 alkoxy, halo, hydroxy, -COOH, C1-C4 alkoxycarbonyl, alyloxycarbonyl, -CONR3R4, -NR3R4, -S(O)p(C1-C4 alkyl), -SO2NR3R4, halo(C1-C4)alkyl, C1-C4 alkoxy(C1-C4)alkyl, R3R4NCO(C1-C4)alkyl, aryl, arylalkyl het1 and het1(C1-C4)alkyl, and/or by an oxido substituent on a ring nitrogen neteroatom when ""het"" includes a pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl group; and ""het"", used in the definition of ""het"", means furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, each optionally substituted by 1 or 2 C1-C4 alkyl substituents, together with the preparation of, compositions containing, the uses of and intermediates used in the synthesis of, such compounds. The compounds are useful as NMDA receptor antagonists for treating acute neurodegenerative and chronic neurological disorders. |
| priorityDate | 1996-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 374.